<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604719</url>
  </required_header>
  <id_info>
    <org_study_id>TXA&amp;Ethamsylate-PPH</org_study_id>
    <nct_id>NCT02604719</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Ethamsylate For Preventing PPH in Patient Undergoing LSCS at High Risk For PPH</brief_title>
  <official_title>Tranexamic Acid and Ethamsylate For Preventing Post Partum Hemorrhage in Patient Undergoing LSCS at High Risk For Post PartumHemorrhage : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Alanwar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of low dose of Tranexamic acid (1gm) and
      Ethamsylate (1gm) after prophylactic oxytocin administration versus placebo with prophylactic
      oxytocin given in the 2 minutes after child delivery in patient undergoing LSCS at high risk
      for post partum hemorrhage
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Question:

      Is the combination of Tranexamic acid and Ethamsylate is more effective than oxytocin alone
      for preventing postpartum hemorrhage if they are given after delivery of the fetus ?
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPH defined as blood loss ≥500 cc</measure>
    <time_frame>the first 24hours</time_frame>
    <description>measured by pads placed under women buttocks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe PPH (&gt;1000 cc), .</measure>
    <time_frame>first 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>tanexamic acid and Ethamsylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml normal saline will be administered intravenously just after birth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid and Ethamsylate</intervention_name>
    <description>The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.</description>
    <arm_group_label>tanexamic acid and Ethamsylate</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>kapron and dycinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women undergoing elective caesarean section

          2. Patient having one or more risk factor for PPH

               -  Multiple pregnancy

               -  Polyhydramnios (AFI &gt;25cm)

               -  Macrocosmic baby (&gt;4.5 Kg)

               -  Prolonged , augmented and obstructed labour

               -  Obese patients(BMI &gt;30)

               -  Premature rapture of membranes

               -  Previous history of PPH

          3. Age ≥18 years

          4. Gestational Age ≥ 35 Weeks

          5. Informed Oral Consent From The Patient

        Exclusion Criteria:

          1. History of venous thrombosis (DVT and/or Pulmonary embolism) OR arterial thrombosis
             (angina pectoris , myocardial infarction, stroke)

          2. History of epilepsy or seizure

          3. Any Known Cardiovascular , renal or liver Disease

          4. Autoimmune Diseases

          5. Sickle Cell Disease

          6. Severe hemorrhagic Disease

          7. Placenta Previa.

          8. Morbidly adherent Placenta

          9. Abruptio placenta

         10. Eclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome

         11. Administration Of low molecular weight heparin or Anti platelets the week before
             delivery .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ahmed Dr alanwar, MD</last_name>
    <phone>+201111486669</phone>
    <phone_ext>0020</phone_ext>
    <email>eladwar@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ahmed Dr kotb, MD</last_name>
    <phone>+201008681999</phone>
    <phone_ext>0020</phone_ext>
    <email>ahmedmkotp@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Alanwar</investigator_full_name>
    <investigator_title>dr.ahmed alanwar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Ethamsylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

